Arcus Biosciences (RCUS) Long-Term Investments (2017 - 2026)

Arcus Biosciences has reported Long-Term Investments for 10 years, with the latest figure at $54.0 million in Q1 2026.

• For the quarter ending Q1 2026, Long-Term Investments rose 575.0% year-over-year to $54.0 million; the trailing twelve-month figure through Mar 2026 stood at $54.0 million (up 575.0% YoY), and the FY2025 full-year result was $29.0 million, up 107.14% from the prior year.
• Long-Term Investments for Q1 2026 stood at $54.0 million, up from $29.0 million in the prior quarter.
• The five-year high for Long-Term Investments was $151.0 million in Q3 2023, with the low at $2.0 million in Q3 2024.
• Average Long-Term Investments over 5 years is $70.6 million, with a median of $80.0 million recorded in 2023.
• Year-over-year, Long-Term Investments tumbled 98.68% in 2024 and soared 575.0% in 2026.
• Tracing RCUS's Long-Term Investments over 5 years: stood at $129.0 million in 2022, then slipped by 17.05% to $107.0 million in 2023, then tumbled by 86.92% to $14.0 million in 2024, then soared by 107.14% to $29.0 million in 2025, then soared by 86.21% to $54.0 million in 2026.
• The last three Long-Term Investments figures came in at $54.0 million (Q1 2026), $29.0 million (Q4 2025), and $10.0 million (Q3 2025), per Business Quant data.

Peer Comparison